Security
INTS · INTENSITY THERAPEUTICS, INC.
INTSNASDAQCommon stockCurrentCIK 1567264Updated Sep 26, 2026
INTS price & chart
Loading TradingView…
NASDAQ:INTS on TradingView ↗About the company
We are a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction leading to anti-cancer immune activation. Our new approach involves the direct injection into tumors of a unique product created from our DfuseRxSM discovery platform.
In the news
Intensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of Common Stock News provided by Intensity Therapeutics Inc. Oct 31, 2025, 08:00 ET Share this article Share to X Share this article Share to X SHELTON, Conn. , Oct. 31, 2025 /PRNewswire/ -- Intensity Therapeutic ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 14,101,000Source | 4,783,000Source | 17,295,000Source | 1,757,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 11,921,000Source | 2,590,000Source | 8,556,000Source | 1,312,000Source |
| Assets, CurrentUSD | 12,709,000Source | 3,363,000Source | 15,464,000Source | 1,451,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 788,000Source | 773,000Source | — | — |
| Operating Lease, Right-of-Use AssetUSD | 96,000Source | 122,000Source | 147,000Source | 139,000Source |
| Other Assets, NoncurrentUSD | 1,296,000Source | 1,298,000Source | 1,684,000Source | 167,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 2,225,000Source | 1,865,000Source | 4,133,000Source | 6,855,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 0Source | 2,000Source | 1,000Source | 0Source |
| Additional Paid in CapitalUSD | 90,265,000Source | 69,699,000Source | 63,676,000Source | 23,555,000Source |
| Retained Earnings (Accumulated Deficit)USD | -78,389,000Source | -66,783,000Source | -50,515,000Source | -38,653,000Source |
| Stockholders' Equity Attributable to ParentUSD | 11,876,000Source | 2,918,000Source | 13,162,000Source | -15,098,000Source |
| Liabilities and EquityUSD | 14,101,000Source | 4,783,000Source | 17,295,000Source | 1,757,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 2,146,000Source | 1,755,000Source | 3,959,000Source | 6,819,000Source |
| Operating Lease, Liability, CurrentUSD | 31,000Source | 28,000Source | 20,000Source | 143,000Source |
| Accounts Payable, CurrentUSD | 583,000Source | 1,219,000Source | 3,048,000Source | 603,000Source |
| Operating Lease, Liability, NoncurrentUSD | 79,000Source | 110,000Source | 138,000Source | 0Source |
| Other Liabilities, NoncurrentUSD | — | 0Source | 36,000Source | 36,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 1,532,000Source | 508,000Source | 891,000Source | 1,724,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 11,900,000Source | 2,600,000Source | 14,800,000Source | — |
| Dividends PayableUSD | — | 0Source | 1,324,000Source | 0Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 2,000,000Source | 3,073,000Source | 1,398,000Source | 1,169,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -9,233,000Source | -15,220,000Source | -7,205,000Source | -5,477,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 0Source | 6,354,000Source | -6,023,000Source | 0Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 18,564,000Source | 2,900,000Source | 20,472,000Source | 2,250,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 9,331,000Source | -5,966,000Source | 7,244,000Source | -3,227,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 11,921,000Source | 2,590,000Source | 8,556,000Source | 1,312,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 2,000,000Source | 3,073,000Source | 1,398,000Source | 1,169,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 11,900,000Source | 2,600,000Source | 14,800,000Source | — |
| Dividends PayableUSD | — | 0Source | 1,324,000Source | 0Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | 0Source | -2,262,000Source | 0Source |
| General and Administrative ExpenseUSD | 5,187,000Source | 6,089,000Source | 3,533,000Source | 2,418,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| InterestExpenseNonoperatingUSD | — | 0Source | — | — |
| Investment Income, InterestUSD | 180,000Source | 314,000Source | 324,000Source | 2,000Source |
| Net Income (Loss) Attributable to ParentUSD | -11,606,000Source | -16,268,000Source | -10,538,000Source | -7,582,000Source |
| Operating ExpensesUSD | 11,972,000Source | 16,585,000Source | 8,319,000Source | 7,550,000Source |
| Operating Lease, ExpenseUSD | 34,000Source | 34,000Source | 63,000Source | 120,000Source |
| Other Nonoperating Income (Expense)USD | 186,000Source | — | — | — |
| Proceeds from Issuance of Long-term DebtUSD | — | 0Source | 230,000Source | 2,250,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -11,972,000Source | -16,585,000Source | -8,319,000Source | -7,550,000Source |
| Other Nonoperating Income (Expense)USD | 186,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -11,606,000Source | -16,268,000Source | -10,538,000Source | -7,582,000Source |
| Earnings Per Share, BasicUSD per share | -8.56Source | -1.17Source | -1.38Source | -2.22Source |
| Earnings Per Share, DilutedUSD per share | -8.56Source | -1.17Source | -1.38Source | -2.22Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 1,356,358Source | 13,906,973Source | 8,616,324Source | 3,410,103Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 1,356,358Source | 13,906,973Source | 8,616,324Source | 3,410,103Source |
| Interest Expense (non-operating)USD | — | 0Source | — | — |
| Additional Financial Items | ||||
| General and Administrative ExpenseUSD | 5,187,000Source | 6,089,000Source | 3,533,000Source | 2,418,000Source |
| Interest ExpenseUSD | — | — | 305,000Source | 82,000Source |
| Investment Income, InterestUSD | 180,000Source | 314,000Source | 324,000Source | 2,000Source |
| Net Income (Loss) from Continuing Operations Available to Common Shareholders, BasicUSD | — | -16,268,000Source | -11,862,000Source | -7,582,000Source |
| Operating ExpensesUSD | 11,972,000Source | 16,585,000Source | 8,319,000Source | 7,550,000Source |
| Operating Lease, ExpenseUSD | 34,000Source | 34,000Source | 63,000Source | 120,000Source |
| Preferred Stock Dividends, Income Statement ImpactUSD | — | 0Source | 1,324,000Source | 0Source |
| Research and Development ExpenseUSD | 6,785,000Source | 10,496,000Source | 4,786,000Source | 5,132,000Source |
Offerings
Registration 333-286683
- Gross proceeds
- 2349999.75
- Net proceeds
- 2185499.77
- Deal price
- 0.75
- Shares
- 3133333
- Offering price
- $0.75
- Ticker
- INTS